For our clients in the cord blood banking sector, we highly recommend that you review the report, “Mesenchymal Stem Cells – Advances & Applications.” This MSC report will uniquely inform you about opportunities related to cord tissue storage and future applications with cord tissue derived MSCs.
Remember, to benefit from the global MSC market, you need to anticipate and serve the needs of your clients – or other cord blood banks will.
Key questions answered in the report are:
(Regenerative Medicine = RM; Cell Therapy= CT)
- How many companies are currently supporting the regenerative medicine (RM) industry?
- What is the current regional breakdown of RM industry?
- How many RM products have been approved?
- What are the types of diseases are currently being pursued by RM companies?
- What are the major financial events, partnerships and acquisitions in RM sector?
- How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
- What are the major anticipated RM clinical events in 2015-16?
- What are the major therapeutic opportunities for the big pharma in RM and CT?
- How many CT product candidates have reached the Phase IIIstage and what are they?
- What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
- What are the major commercially available CT products?
- What is the total number of CT clinical trials at the global level?
- What are the major cell types used in CT clinical trials?
- What are the major indications addressed by CT clinical trials?
- What are the major CT clinical trials that have reached Phase III?
- How many CT clinical trials failed in the past year and what are they?
- What are the contributions of MSCs to the cell therapy industry?
- What are the biological properties of MSCs?
- What do MSCs get differentiated into?
- What bioactive molecules do the MSCs secrete?
- What are the immunomodulatory functions of MSCs?
- What are the factors impacting the acquisition of MSCs?
- What are the various sources of MSCs?
- What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
- What are the major clinical trials focusing on diabetes using BMMSCs?
- What are the major clinical trials involving BMMSCs for cardiovascular diseases?
- What are the major clinical trials focusing on liver diseases by BMMSCs?
- What are the brain-related diseases addressed by clinical trials using BMMSCs?
- How many clinical trials are conducted for intestinal diseases using MSCs?
- What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
- Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
- What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
- What is the current number of clinical trials using MSCs?
- How many major clinical trials using MSCs have reached the Phase III?
- What are the MSCs-based cell therapy products available in the market?
- What is the current size of the MSC marketplace?
Key findings within this report include:
- Trend rate data for MSC grants, clinical trials, scientific publications, and patents
- Recent advances in MSC research and clinical applications
- Market size determinations, including future projections through 2020
- Deal-making within the MSC marketplace, including key acquisitions and partnerships
- Competitive assessment of the MSC marketplace, by market segment
- Research priorities by market segment
- Top influencers with the MSC marketplace
- Social analytics for the MSC marketplace
- Twitter User Data, Google Trends User Data, Google Adwords Costs, and Hashtag
- Overview of the broader regenerative medicine (RM) and cell therapy (CT) marketplace
- Company profiles for 35 MSC industry leaders
Summary of Key Value Points for Cord Blood Banks
In summary, “Mesenchymal Stem Cells – Advances & Applications” is a must-read industry report for cord blood banks to optimally position themselves to sell MSC products and services, such as cord tissue storage. Furthermore, diversification is becoming a common theme at cord blood banks, with multiple types of stem cell storage now being offered by many providers. One of the more common types of storage offered at a diversified stem cell bank is adipose tissue storage, a tissue type which also contains MSCs.
The 250 page report is also covered by BioInformant’s Greater than 100% Money Back Guarantee.
Remember, to profit from this lucrative and rapidly expanding MSC market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the marketplace, and take advantage of crucial trends.
Claim it now to profit from this expanding market – or other cord blood banks will: https://www.bioinformant.com/product/mesenchymal-stem-cells-advances-and-applications
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Becton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.